"Sale Intended for Tax Payment, But Decided It Would Harm Corporate Value"

"We Follow a Profit-Sharing Supply Model, Not Technology Transfer"

"FDA Pre-ANDA Meeting Approved; Early in Development, But Procedures Are Underway"

Jeon Inseok, CEO of Samchundang Pharm, has announced the withdrawal of the large-scale stake sale (block deal), directly addressing the 'fraud allegations' raised in the market. He stated that he intends to restore trust, which was damaged by controversy over the contract structure and a sharp drop in share price, through business performance.

Inseok Jeon, CEO of Samchundang Pharm, is speaking at a press conference held at the Samchundang Pharm headquarters in Seocho-gu, Seoul, on the 6th. Photo by Jeongyeon Park

Inseok Jeon, CEO of Samchundang Pharm, is speaking at a press conference held at the Samchundang Pharm headquarters in Seocho-gu, Seoul, on the 6th. Photo by Jeongyeon Park

View original image

At a press conference held at the company's headquarters in Seocho-dong, Seocho-gu, Seoul on the 6th, CEO Jeon said, "A normal sale plan intended for paying personal taxes has been distorted through a malicious frame, damaging even the value of the company," adding, "To break the narrative of a fraud, I decided to withdraw the block deal itself."


Previously, CEO Jeon had pursued a stake sale worth about 250 billion won, but suspicions about exaggeration of a U.S. contract became entangled with the deal, fueling controversy over 'selling at the peak.' He explained that this sale was an unavoidable choice to raise funds for taxes such as gift tax and capital gains tax.


According to CEO Jeon, the amount of taxes that he and his spouse must pay is about 233.5 billion won. Of this, the gift tax accounts for about 124 billion won, while capital gains tax and other taxes related to the stock sale amount to around 70 billion won. He stated that a portion of the taxes had already been paid using a stock-collateralized loan, and that he had pursued the block deal to secure the remaining funds. He added that, considering share price volatility, he set the sale amount at about 250 billion won, including some contingency funds.


As the controversy over the stake sale extended to doubts about the contract's size and structure, CEO Jeon emphasized that the company's business model is fundamentally different from traditional biotech firms.


According to CEO Jeon, Samchundang Pharm develops and manufactures generic and biosimilar products in-house, then sells them through global partners under a 'product supply-based profit-sharing contract.' Typically, profits are split 50-50, and the contract includes a binding condition allowing termination if the partner fails to achieve a certain level of sales. He explained that while initial milestone payments may be limited, the total contract value can vary significantly depending on future sales performance.


In response to the market's concerns over 'contract size,' he argued that even if the disclosed contract payments and milestones are small, it does not mean the total contract value is small. CEO Jeon stated, "While many domestic biotech companies receive upfront payments and milestones through technology transfer, Samchundang Pharm operates under a product supply-based contract," adding, "Milestones are merely partial development costs divided as initial payments within the entire contract." He further explained, "The key is that we share profits generated from supplying products over the next 10 years or more with our partners. Therefore, we do not enter into contracts based solely on milestones."


During the press conference, a document from the U.S. Food and Drug Administration (FDA) concerning the development of oral semaglutide was also released. This appears to be an effort to dispel doubts about the substance of the contract and the company’s technological capabilities.


The document confirmed that a request for a 'Pre-ANDA (Product Development Meeting)'—an initial step in the generic drug development process—had been approved. This is a preliminary discussion stage with the FDA’s generic drugs department, corresponding to the early development phase before clinical trials or regulatory approval. CEO Jeon said, "It is by no means easy to reach the stage of applying for clinical trials with the FDA," adding, "We are undergoing the process of technological verification and data collection required by global partners."

Jeon Inseok, CEO of Samchundang Pharmaceutical, is explaining the company's core technology 'S-PASS' at a press conference held on the 6th at the Samchundang Pharmaceutical headquarters in Seocho-gu, Seoul. Photo by Park Jungyeon

Jeon Inseok, CEO of Samchundang Pharmaceutical, is explaining the company's core technology 'S-PASS' at a press conference held on the 6th at the Samchundang Pharmaceutical headquarters in Seocho-gu, Seoul. Photo by Park Jungyeon

View original image

At the press conference, questions were also raised about the company's claim that regulatory approval for the oral semaglutide generic under development can be obtained solely through a bioequivalence study. When asked whether the company could disclose data proving the drug’s efficacy, the company responded, "We have secured some initial pharmacokinetic (PK) data, but only limited figures have been made public." Ultimately, whether the main indicators in future bioequivalence tests are confirmed to be on par with the reference drug is expected to be a critical juncture for technological validation.



Regarding the series of controversies, CEO Jeon stated, "There has been absolutely no exaggeration or falsehood in the contract announcements," adding, "Rather than responding to rumors, we will restore trust through actual business results and present future milestones and performance as concrete outcomes."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing